Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1041 • ACR Convergence 2023
Efficacy of Apremilast on Peripheral and Axial Inflammation in Patients with Psoriatic Arthritis Based on Whole-Body Magnetic Resonance Imaging
Mikkel Østergaard¹, Mikael Boesen², Walter P. Maksymowych³, Robert Lambert⁴, Guillermo Valenzuela⁵, Michael Bubb⁶, Olga Kubassova⁷, Jyotsna Reddy⁸, Stephen Colgan⁹, Yuri Klyachkin¹⁰, Cynthia Deignan¹¹, Zhenwei Zhou⁸ and Philip J. Mease¹², ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ²Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Naerum, Denmark, ³Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁴Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, ⁵Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁶University of Florida, Gainesville, FL, ⁷Image Analysis Group, Philadelphia, PA, ⁸Amgen, Inc., Thousand Oaks, CA, ⁹Amgen, Inc., Halton Hills, ON, Canada, ¹⁰Amgen, Inc., Lexington, KY, ¹¹Amgen, Inc., Agoura Hills, CA, ¹²Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Apremilast is an oral phosphodiesterase 4 inhibitor with a unique immunomodulatory mechanism of action and is approved for the treatment of psoriatic arthritis (PsA).…
Abstract Number: 1416 • ACR Convergence 2023
Improvement of Work Absenteeism Following Start of Methotrexate Monotherapy in Newly-Diagnosed Psoriatic Arthritis
Ulf Lindström¹, Daniela Di Giuseppe², Sofia Exarchou³, Gerd-Marie Alenius⁴, Tor Olofsson⁵, Eva Klingberg¹, Lennart Jacobsson⁶, Johan Askling² and Johan Karlsson Wallman⁵, ¹University of Gothenburg, Gothenburg, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Lund University, Åkarp, Sweden, ⁴Umeå University, Umeå, Sweden, ⁵Lund University and Skåne University Hospital, Lund, Sweden, ⁶University of Gothenburg, Malmö, Sweden
Background/Purpose: In many countries, methotrexate (MTX) monotherapy is the first-line disease-modifying anti-rheumatic drug (DMARD) therapy for psoriatic arthritis (PsA), despite that its efficacy in PsA…
Abstract Number: 1433 • ACR Convergence 2023
Bimekizumab Impact on Core Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Domains for Patients with Psoriatic Arthritis: 52-Week Results from Four Phase 3 Studies
Joseph Merola¹, Philip J. Mease², Atul Deodhar³, Barbara Ink⁴, Carmen Fleurinck⁵, Rajan Bajracharya⁴, Jason Coarse⁶ and Laura Coates⁷, ¹Harvard Medical School, Brigham and Women's Hospital, Newton, MA, ²Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ³Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Oosterzele, Belgium, ⁶UCB Pharma, Morrisville, NC, ⁷University of Oxford, Oxford, United Kingdom
Background/Purpose: The Group for Research and Assessment of Psoriasis and PsA (GRAPPA) domain‑based treatment recommendations for PsA focus on six key domains: peripheral arthritis, axial…
Abstract Number: 1687 • ACR Convergence 2023
Sex of the Patient Affects Response to Advanced Therapies in Psoriatic Arthritis: Meta-analysis of Data from Randomized Controlled Trials
Lihi Eder¹, Sivakami Mylvaganam², Jordi Pardo Pardo³, Jennifer Petkovic⁴, Vibeke Strand⁵, Philip J. Mease⁶ and Keith Colaco⁷, ¹Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ²Department of Biochemistry, University of Toronto, Toronto, ON, Canada, ³Cochrane Musculoskeletal, University of Ottawa, Ottawa, ON, Canada, ⁴Cochrane Equity Methods Group, University of Ottawa, Ottawa, ON, Canada, ⁵Stanford University, Portola Valley, CA, ⁶Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ⁷Women’s College Research Institute / Department of Health and Society, University of Toronto, Toronto, ON, Canada
Background/Purpose: Limited information exists on participation and study outcomes by sex in randomized controlled trials (RCTs) among patients with psoriatic arthritis (PsA). Through a systematic…
Abstract Number: 1891 • ACR Convergence 2023
Effect of Apremilast on Disease Interception in Patients with Psoriasis at Increased Risk of Developing PsA – Results of the Prospective Interventional Epos Trial
David Simon¹, Ioanna Minopoulou¹, Sara Bayat¹, Koray Tascilar¹, Melek Yalcin Mutlu¹, Filippo Fagni¹, Georg Schett² and Arnd Kleyer³, ¹Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, ²Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ³Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Entheseal bone changes occur in a substantial proportion of psoriasis patients [1] and are associated with an increased risk of developing psoriatic arthritis (PsA)…
Abstract Number: 2239 • ACR Convergence 2023
Achievement of Disease Control in PsA Patients Treated with Upadacitinib at Week 152: Post Hoc Analysis of the Long-term Extensions of Two Phase 3 Trials
Arthur Kavanaugh¹, Kristi Mizelle², Oliver FitzGerald³, Enrique Soriano⁴, Peter Nash⁵, Sandra Ciecinski⁶, Limei Zhou⁶, Arathi Setty⁶ and Laure Gossec⁷, ¹Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ²Tidewater Physicians Multispecialty Group, Newport News, VA, ³Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ⁴Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵School of Medicine, Griffith University, Brisbane, Australia, ⁶AbbVie, Inc., North Chicago, IL, ⁷Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: A main goal of therapy for patients (pts) with PsA is to achieve and maintain the lowest possible level of disease activity across domains.1…
Abstract Number: 2256 • ACR Convergence 2023
The Impact of Clinical Trial Metrics in Psoriatic Arthritis
Maxine Yarnall and Kara Murray, Spherix Global Insights, Exton, PA
Background/Purpose: Rheumatologists have access to a plethora of advanced biologic and small molecule agents for the treatment of psoriatic arthritis (PsA). Prior to FDA approval,…
Abstract Number: 0352 • ACR Convergence 2023
Musculoskeletal Ultrasound Findings in Children with Psoriasis
Laura Nedorezov, Tracy Ting and Patricia Vega-Fernandez, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The presentation of juvenile psoriatic arthritis (JPsA) in children with psoriasis can be insidious and poses a diagnostic challenge. Musculoskeletal ultrasound (MSUS) has emerged…
Abstract Number: 0495 • ACR Convergence 2023
Prevalence of Undiagnosed Inflammatory Bowel Disease in Patients with Spondyloarthritis: EISER Study
Jesus Sanz¹, Zulema Plaza², Jordi Gratacos Masmitja³, Iago Rodríguez -Lago⁴, Elisa Trujillo⁵, Ignacio Marin-Jimenez⁶, Eva Perez-Pampin⁷, Manuel Barreiro de Acosta⁸, Antonio Aznar Esquivel⁹, Marta Carrillo Palau¹⁰, Maria Luz Garcia Vivar¹¹, Maria Carmen Muñoz¹², Lourdes Ladehesa Pineda¹³, Eva Iglesias Flores¹⁴, carolina Merino¹⁵, Yago gonzalez-Lama¹⁶, Marta Arévalo Salaet¹⁷, Xavier calvet¹⁸, Anahy Maria Brandy-Garcia¹⁹, Marta Izquierdo Romero²⁰, SARA MANRIQUE²¹, Raúl Olmedo²², Jose Francisco Garcia Llorente²³, Sandra Pérez²⁴, Inmaculada Ros²⁵, Nuria Rull²⁶, Jose Antonio Pinto Tasende²⁷, Patricia Ucha Abal²⁸, Carlos M González²⁹, Fernando José Rodríguez Martínez³⁰, Soledad Serrano Ladron de Guevara³¹, Marta Domínguez³², Francisco Javier Prado³³, Enrique González-Dávila³⁴ and Ana Gutierrez-Casbas³⁵, ¹Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ²Universidad Autónoma de Madrid, Madrid, Spain, ³University Hospital Parc Taulí, Sabadell, Spain, ⁴Gastroenterology department Hospital Galdakao, Galdakao, Spain, ⁵Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁶Public Health System, Madrid, Spain, ⁷Rheumatology Department Complejo Hospitalario Universitario Santiago, Santiago de compostela, Spain, ⁸Gastroenterology department Complejo Hospitalario Universitario Santiago, Santiago de compostela, Spain, ⁹Rheumatology Department Hospital Universitario Canarias, Santa Cruz de Tenerife, Spain, ¹⁰Gastroenterology department Hospital Universitario Canarias, Santa Cruz de Tenerife, Spain, ¹¹Basurto University Hospital, Bilbao, Spain, ¹²Gastroenterology department Basurto Hospital, Bilbao, Spain, ¹³Rheumatology Department Reina Sofia Universitary Hospital, Cordoba, Spain, ¹⁴Gastroenterology department Hospital Reina Sofia, Cordoba, Spain, ¹⁵Rheumatology Department Hospital Universitario Puerta de Hierro, Majadahonda (Madrid), Spain, ¹⁶Gastroenterology department Hospital Puerta de Hierro Majadahonda, Majadahonda, Spain, ¹⁷Rheumatology Department University Hospital Parc Taulí, Sabadell, Spain, ¹⁸Gastroenterology department University Hospital Parc Taulí, Sabadell, Spain, ¹⁹Hospital Germans Trias i Pujol, Badalona, Spain, ²⁰Gastroenterology department Hospital Cabueñes, Gijon, Spain, ²¹Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ²²Gastroenterology department Hospital Regional Universitario Málaga, Malaga, Spain, ²³Hospital de Gadakao Usansolo Osakidetza, Bilbao, Spain, ²⁴Gastroenterology department Hospital Galdakao, Galdakao, Spain, ²⁵Rheumatology Department HUSLL, Palma de Mallorca, Spain, ²⁶Gastroenterology department HUSLL, Palma de Mallorca, Spain, ²⁷Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ²⁸Gastroenterology department Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ²⁹Rheumatology Department Hospital Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ³⁰Rheumatology Department Hospital Universitario General Santa Lucia, Murcia, Spain, ³¹Gastroenterology department Hospital Universitario General Santa Lucia, Murcia, Spain, ³²Sociedad Española de Reumatología, Madrid, Spain, ³³Research department Hospital Infantil de México Federico Gómez, Mexico City, Mexico, ³⁴Department of Mathematics, Statistics and Operation Reseach La Laguna University, La Laguna, Spain, ³⁵Gastroenterology department Hospital General Universitario de. Dr. Balmis de Alicante Servicio Digestivo. ISABIAL y CIBERehd, Alicante, Spain
Background/Purpose: EISER is a cross-sectional, multicenter, observational, SER-GETECCU cooperative study involving 13 Spanish hospitals whose main objective was to estimate the prevalence of undiagnosed Inflammatory…
Abstract Number: 0527 • ACR Convergence 2023
Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies
M. Elaine Husni¹, Philip J. Mease², Joseph Merola³, Frank Behrens⁴, Ennio G Favalli⁵, Dennis McGonagle⁶, William R Tillett⁷, Shigeyoshi Tsuji⁸, Barbara Ink⁹, Rajan Bajracharya⁹, Jérémy Lambert¹⁰, Jason Coarse¹¹ and Laure Gossec¹², ¹Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, ²Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ³Harvard Medical School, Brigham and Women's Hospital, Newton, MA, ⁴Goethe University, Division of Rheumatology, University Hospital and Fraunhofer Institute for Translational Medicine & Pharmacology, Frankfurt, Germany, ⁵ASST Gaetano Pini-CTO, University of Milan, Department of Rheumatology, Milan, Italy, ⁶Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, ⁷Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸Nippon Life Hospital, Osaka, Japan, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Irigny, France, ¹¹UCB Pharma, Morrisville, NC, ¹²Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: Pain and fatigue have been identified by patients (pts) as key features of PsA, driving the impact on their health-related quality of life.1 Bimekizumab…
Abstract Number: 1044 • ACR Convergence 2023
Prevalence and Distribution of Sonographic Elementary Lesions in PsA – Results of 2 Cohorts
Ari Polachek¹, Victoria Furer², Sydney Thib³, Liran Mendel², Ori Elkayam² and Lihi Eder⁴, ¹Sourasky Medical Center, Tel Aviv, Israel, ²Tel Aviv Medical Center, Tel Aviv, Israel, ³Women’s College Research Institute, Toronto, ON, Canada, ⁴Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) can manifest with different musculoskeletal (MSK) features. Ultrasound (US) optimizes the assessment of the different MSK features in PsA. However, there…
Abstract Number: 1418 • ACR Convergence 2023
Efficacy of the Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active PsA: Results from a Phase 2 Trial
Alice B. Gottlieb¹, April W. Armstrong², Joseph Merola³, Andrew Napoli⁴, Miroslawa Nowak⁴, Subhashis Banerjee⁴, Thomas Lehman⁵ and Philip J. Mease⁶, ¹Icahn School of Medicine at Mount Sinai, New York, NY, ²Keck School of Medicine of University of Southern California, Los Angeles, CA, ³Harvard Medical School, Brigham and Women's Hospital, Newton, MA, ⁴Bristol Myers Squibb, Princeton, NJ, ⁵Bristol Myers Squibb, Philadelphia, PA, ⁶Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Tyrosine kinase 2 (TYK2) mediates signaling of key cytokines involved in plaque psoriasis (PsO) and PsA pathophysiology. Deucravacitinib is a first-in-class, oral, selective, allosteric…
Abstract Number: 1434 • ACR Convergence 2023
Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 2 Trial
Andrew Östör¹, Filip Van den Bosch², Kim A Papp³, Cecilia Asnal⁴, Ricardo Blanco⁵, Jacob Aelion⁶, Vassilis Stakias⁷, Thomas Iyile⁷, Kyle Carter⁷, Ahmed Soliman⁷, Leonidas Drogaris⁷, Michael Chen⁷, Byron Padilla⁷ and Alan Kivitz⁸, ¹Monash University & Emeritus Research; Australian National University, Melbourne, Australia, ²Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ³Alliance Clinical Research and Probity Medical Research, Waterloo, and University of Toronto, Toronto, ON, Canada, ⁴Hospital Alemán, Buenos Aires, Argentina, ⁵Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁶West Tennessee Research Institute, Jackson, TN, ⁷AbbVie, Inc., North Chicago, IL, ⁸Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: PsA is a chronic systemic inflammatory disease that affects 30% of patients diagnosed with psoriasis, with a clinical burden that includes dactylitis, enthesitis, cutaneous…
Abstract Number: 1688 • ACR Convergence 2023
Izokibep Demonstrates Major Disease Control on ACR70, PASI100 and Enthesitis Resolution in Patients with Active Psoriatic Arthritis Treated Through 46 Weeks
Philip J. Mease¹, Peter C. Taylor², Kurt de Vlam³, Paul M. Peloso⁴, Apinya Lertratanakul⁵, Dieter Wetzel⁶, Nikolai Brun⁷, Brian Wiens⁸, Jan Brandt-Juergens⁹, Edit Drescher¹⁰, Eva Dokoupilova¹¹, Anna Rowińska-Osuch¹², Nadia Abdel-Kader Martin¹³ and Frank Behrens¹⁴, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ²Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³University Hospitals Leuven, Leuven, Belgium, ⁴ACELYRIN, INC., Naples, FL, ⁵ACELYRIN, Chicago, IL, ⁶toclinco GmbH, Freiburg im Breisgau, Germany, ⁷Affibody AB, Solna, Sweden, ⁸ACELYRIN, Inc., Half Moon Bay, CA, ⁹rheumatologische Schwerpunktpraxis, Berlin, Germany, ¹⁰Csolnoky Ferenc Hospital / Vital Medical Center Private Clinci, Veszprém, Hungary, ¹¹Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology; MEDICAL PLUS sro, Brno, Czech Republic, ¹²ETG Warszawa, Warsaw, Poland, ¹³Hospital Quironsalud Infanta Luisa, Sevilla, Spain, ¹⁴Goethe University, Division of Rheumatology, University Hospital and Fraunhofer Institute for Translational Medicine & Pharmacology, Frankfurt, Germany
Background/Purpose: IL-17 inhibition demonstrates efficacy in multiple disease domains in psoriatic arthritis. Izokibep is a unique IL-17A inhibitor with high IL-17A binding affinity (KD= 0.3…
Abstract Number: 2077 • ACR Convergence 2023
A Curriculum of Online Education Significantly Improved Rheumatologists’ Knowledge, Competence and Confidence in Managing Patients with Spondyloarthritis
Elaine Bell¹, Marinella Calle² and Iain McInnes³, ¹Medscape Global Education, London, United Kingdom, ²MEDSCAPE GLOBAL, London, United Kingdom, ³University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are challenging conditions for rheumatologists to manage. There is an increasing focus on virtual training modalities post-pandemic.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].